Company Overview
Snapshot
Founded in November 2020 by Dana Cohen, Liora Madar Shapiro, and Tal Peleg-Shulman, BioMe operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on research and development.
Business overview
BioMe offers a platform for personal microbiome processing, restoration, storage, and analytics within the Health Tech & Life Sciences sector. The company's core technology involves safe, dry, and odor-free microbiome capsules designed for healthy adults. These self-microbiome capsules aim to accelerate the natural restoration of gut microbiota, which can be eradicated by various medical treatments such as antibiotics, antidepressants, laxatives, and chemotherapy. BioMe serves markets in North America and Asia, operating within the broader Pharmaceuticals and Precision Medicine categories.
Log in to access full profile ›Company Intelligence Q&A
- What is BioMe's primary focus?
- BioMe focuses on microbiome restoration and analytics, developing a platform for personal microbiome processing, storage, and analysis.
- When was BioMe founded and by whom?
- BioMe was founded in November 2020 by Dana Cohen, Liora Madar Shapiro, and Tal Peleg-Shulman.
- What is the main product offered by BioMe?
- BioMe offers safe, dry, and odor-free microbiome capsules for healthy adults, designed to accelerate the natural restoration of gut microbiota.
- Which industries does BioMe serve?
- BioMe serves the Health Tech & Life Sciences sector, with a focus on pharmaceuticals and healthcare, targeting patients who may have compromised gut microbiota due to various medical treatments.
- What is BioMe's current development stage?
- BioMe is currently in the Pre-Funding stage, with its products in the R&D phase.